Table 1 Clinicopathological information of ovarian cancer patients (n = 112)

 Age (years), median (range)

56 (36–74)

 Neoadjuvant chemotherapy (%)

14 (12.5%)

Histology

 High-grade serous carcinoma

95 (84.8%)

 Clear cell carcinoma

9 (8.03%)

 Endometrioid

2 (1.8%)

 Mucinous

2 (1.8%)

 Carcinosarcoma

3 (2.7%)

 Squamous

1 (0.9%)

FIGO stage (%)

 I

15 (13.4%)

 II

5 (4.5%)

 III

64 (57.1%)

 IV

28 (25.0%)

 Pre-treatment serum CA 125 (U/mL), median (range)

746.4 (10–5000)^a

Residual disease (%)

  ≤ 1 cm (optimal)

88 (78.6%)

  > 1 cm (suboptimal)

24 (21.4%)

Platinum response (%)^b

 Sensitive

45 (76.3%)

 Resistant

14 (23.7%)